Clinical review demonstrates risk-adapted imaging and biomarker surveillance in high-risk liver disease, indicating improved early tumor detection alongside cost-effectiveness.
Hepatocellular carcinoma surveillance requires risk-adapted use of US, MRI, and emerging biomarker-based strategies to optimize early detection and clinical outcomes while maintaining cost-effectiveness and real-world feasibility.
No takes yet. Share an insight, caveat, or question.
Fowler et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: